As a result, 76 of the 90 (84.4%) lesions were matched with histological diagnoses using a combination of NBI-ME and EME.Ī combination of NBI-ME and EME was useful in predicting the histological type of depressed-type EGC.Īcetic acid Diagnosis Early gastric cancer Magnifying endoscopy Narrow band imaging. These unclassified lesions were then evaluated for MS patterns using EME, which classified 33 (81.0%) lesions as MS patterns, diagnosed as differentiated adenocarcinoma. However, 42 of the 90 (46.7%) lesions could not be classified into MV patterns by NBI-ME. We classified the depressed-type EGCs into the following 2 MV patterns using NBI-ME: a fine-network pattern that indicated differentiated adenocarcinoma (25/25, 100%) and a corkscrew pattern that likely indicated undifferentiated adenocarcinoma (18/23, 78.3%). Subsequently, EGCs unclassified by MV pattern were classified according to MS pattern by enhanced ME (EME) images obtained from the same angle. First, depressed-type EGCs were classified according to MV pattern by NBI-ME. We evaluated the microvascular (MV) and mucosal surface (MS) patterns of depressed-type EGCs using magnifying endoscopy (ME) with narrow-band imaging (NBI) (NBI-ME) and ME enhanced by 1.5% acetic acid, respectively. Ninety depressed-type EGCs in 72 patients were macroscopically and histologically identified. The index is tracked by the iShares Biotechnology Index ( IBB ).To determine whether the endoscopic findings of depressed-type early gastric cancers (EGCs) could precisely predict the histological type. The top ten holdings have a 48.69% allocation. In addition, companies that are engaged in the production of tools or systems that enable biotechnology processes are included. The index was launched in 2012 and includes companies that are engaged in the research and development of therapeutic treatments but are not focused on the commercialization and mass production of pharmaceutical drugs. The ICE Biotechnology Index is a rules-based, modified float-adjusted market capitalization-weighted index that tracks the performance of qualifying U.S. The index is tracked by the First Trust NYSE Arca Biotechnology Index ( FBT ). The index is designed to reflect the performance of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. It constitutes the top 30 large-cap biotech companies and weights them equally. Next in line is the NYSE Arca Biotechnology Index. Direxion Daily S&P Biotech Bull 3X ETF ( LABU).Direxion Daily S&P Biotech Bear 3X ETF ( LABD).In addition, it is tracked by the following: SPDR S&P Biotech ETF ( XBI ) is among the prominent ETFs tracking the index. The index has 186 constituents with the top ten holdings having a 11.8% allocation. The index is modified equal-weighted wherein each constituent has an equal weightage. The S&P Biotechnology Select Industry represents the biotechnology segment of the S&P Total Market Index. It offers a pure play biotech exposure, and follows a modified equal-weighting approach to provide the potential for unconcentrated industry exposure across large-, mid-, and small-cap stocks. The S&P Biotechnology Select Industry Index was launched in January 2006. iShares Nasdaq US Biotechnology UCITS ETF.ProShares UltraShort Nasdaq Biotechnology ETF ( BIS).ProShares Ultra Nasdaq Biotechnology ETF ( BIB).The index is tracked by the Invesco Nasdaq Biotechnology Index ( IBBQ ). Some of the other ETFs currently tracking NBI are: MIRCOS MINIS, DATABASES, MAIL LISTS ACCOUNTING DATA IBM, DEC/VAX, APPLE, WANG H WordPerfect Lotus, Dbase MICOM HCPT, Lanier Mac, NBI DISPLAYWRITER AS/400. The top ten constituents currently add to around 46.67% and include: The resulting split by index weight is approximately 65% and 35%, respectively. ICB currently classifies 230 companies as biotechnology, and the remaining 44 as pharmaceuticals. One of the most interesting aspects of NBI’s composition stems from its subsector classifications, namely, the split between biotechnology and pharmaceuticals. The index is a modified market capitalization weight, so that constituents are capped at 8% (for the top 5) and at 4% (for the remaining) at each quarterly index rebalance. Launched in 1993, the Nasdaq Biotechnology Index uses a modified capitalization-weighted methodology composed of securities of Nasdaq-listed companies classified according to the Industry Classification Benchmark (ICB) as either biotechnology or pharmaceuticals, which also meet other eligibility criteria.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |